메뉴 건너뛰기




Volumn 85, Issue 2, 2013, Pages 210-213

Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene

Author keywords

Acute hepatitis B; Entecavir; HBV mutants; Lamivudine; Nucleos(t)ide analogues; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

EID: 84871084326     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23448     Document Type: Article
Times cited : (7)

References (31)
  • 1
    • 43049174567 scopus 로고    scopus 로고
    • Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    • Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ. 2008a. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 48:895-902.
    • (2008) J Hepatol , vol.48 , pp. 895-902
    • Baldick, C.J.1    Eggers, B.J.2    Fang, J.3    Levine, S.M.4    Pokornowski, K.A.5    Rose, R.E.6    Yu, C.F.7    Tenney, D.J.8    Colonno, R.J.9
  • 3
    • 58549101112 scopus 로고    scopus 로고
    • Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy
    • Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. 2009. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 24:49-54.
    • (2009) J Gastroenterol Hepatol , vol.24 , pp. 49-54
    • Cheong, J.Y.1    Cho, S.W.2    Choi, J.M.3    Hong, S.P.4    Kim, S.O.5    Yoo, W.D.6
  • 4
    • 34848858648 scopus 로고    scopus 로고
    • Four year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patients [Abstract]
    • Colonno RJ, Rose RE, Pokornowski K. 2007. Four year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patients [Abstract]. J Hepatol 46:S294.
    • (2007) J Hepatol , vol.46
    • Colonno, R.J.1    Rose, R.E.2    Pokornowski, K.3
  • 5
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B
    • European Association for the Study of the Liver. . :-. Epub March 20, 2012.
    • European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 57:167-185. Epub March 20, 2012.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 6
    • 79952211991 scopus 로고    scopus 로고
    • Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure
    • Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. 2011. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53:774-780.
    • (2011) Hepatology , vol.53 , pp. 774-780
    • Garg, H.1    Sarin, S.K.2    Kumar, M.3    Garg, V.4    Sharma, B.C.5    Kumar, A.6
  • 7
    • 69549138465 scopus 로고    scopus 로고
    • Entecavir monotherapy for lamivudine-refractory chronic hepatitis B
    • Goulis I, Dalekos GN. 2008. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 6:855-859.
    • (2008) Expert Rev Anti Infect Ther , vol.6 , pp. 855-859
    • Goulis, I.1    Dalekos, G.N.2
  • 8
    • 58249093833 scopus 로고    scopus 로고
    • Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient
    • Guo JJ, Li QL, Shi XF, Zhang DZ, Zeng AZ, Feng T, Huang AL. 2009. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res 81:180-183.
    • (2009) Antiviral Res , vol.81 , pp. 180-183
    • Guo, J.J.1    Li, Q.L.2    Shi, X.F.3    Zhang, D.Z.4    Zeng, A.Z.5    Feng, T.6    Huang, A.L.7
  • 13
    • 65049088247 scopus 로고    scopus 로고
    • The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B
    • McMahon BJ. 2009. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 3:334-342.
    • (2009) Hepatol Int , vol.3 , pp. 334-342
    • McMahon, B.J.1
  • 14
    • 79959577813 scopus 로고    scopus 로고
    • Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B
    • Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. 2011. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat 18:212-216.
    • (2011) J Viral Hepat , vol.18 , pp. 212-216
    • Mirandola, S.1    Campagnolo, D.2    Bortoletto, G.3    Franceschini, L.4    Marcolongo, M.5    Alberti, A.6
  • 15
    • 80053199294 scopus 로고    scopus 로고
    • Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir
    • Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. 2011. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther 34:972-981.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 972-981
    • Ong, A.1    Wong, V.W.2    Wong, G.L.3    Chan, H.Y.4    Tse, C.H.5    Chan, H.L.6
  • 16
    • 80053628299 scopus 로고    scopus 로고
    • Sequencing technologies and genome sequencing
    • Pareek CS, Smoczynski R, Tretyn A. 2011. Sequencing technologies and genome sequencing. J Appl Genet 52:413-435.
    • (2011) J Appl Genet , vol.52 , pp. 413-435
    • Pareek, C.S.1    Smoczynski, R.2    Tretyn, A.3
  • 20
    • 34249075512 scopus 로고    scopus 로고
    • In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents
    • Qi X, Xiong S, Yang H, Miller M, Delaney WE IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12:355-362.
    • (2007) Antivir Ther , vol.12 , pp. 355-362
    • Qi, X.1    Xiong, S.2    Yang, H.3    Miller, M.4    Delaney IV, W.E.5
  • 21
    • 33846531835 scopus 로고    scopus 로고
    • Hepatitis B virus taxonomy and hepatitis B virus genotypes
    • Schaefer S. 2007. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13:14-21.
    • (2007) World J Gastroenterol , vol.13 , pp. 14-21
    • Schaefer, S.1
  • 22
    • 70350050776 scopus 로고    scopus 로고
    • Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone
    • Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. 2009. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 50:1064-1071.
    • (2009) Hepatology , vol.50 , pp. 1064-1071
    • Shim, J.H.1    Suh, D.J.2    Kim, K.M.3    Lim, Y.S.4    Lee, H.C.5    Chung, Y.H.6    Lee, Y.S.7
  • 25
    • 84858288892 scopus 로고    scopus 로고
    • Management of severe acute to fulminant hepatitis B: To treat or not to treat or when to treat
    • Tillmann HL, Zachou K, Dalekos GN. 2012. Management of severe acute to fulminant hepatitis B: To treat or not to treat or when to treat? Liver Int 32:544-553.
    • (2012) Liver Int , vol.32 , pp. 544-553
    • Tillmann, H.L.1    Zachou, K.2    Dalekos, G.N.3
  • 27
    • 34447255407 scopus 로고    scopus 로고
    • The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro
    • Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285-2292.
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 2285-2292
    • Warner, N.1    Locarnini, S.2    Kuiper, M.3    Bartholomeusz, A.4    Ayres, A.5    Yuen, L.6    Shaw, T.7
  • 28
    • 42149123445 scopus 로고    scopus 로고
    • Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence
    • Wiegand J, Hasenclever D, Tillmann HL. 2008. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 13:211-220.
    • (2008) Antivir Ther , vol.13 , pp. 211-220
    • Wiegand, J.1    Hasenclever, D.2    Tillmann, H.L.3
  • 30
    • 77949332709 scopus 로고    scopus 로고
    • The study of efficacy of lamivudine in patients with severe acute hepatitis B
    • Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. 2010. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 55:755-783.
    • (2010) Dig Dis Sci , vol.55 , pp. 755-783
    • Yu, J.W.1    Sun, L.J.2    Zhao, Y.H.3    Kang, P.4    Li, S.C.5
  • 31
    • 84856462833 scopus 로고    scopus 로고
    • Management of treatment failure in chronic hepatitis B
    • Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J Hepatol 56:S112-S122.
    • (2012) J Hepatol , vol.56
    • Zoulim, F.1    Locarnini, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.